SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the publication of the first human SPECT images ...
Perspective Therapeutics, Inc. presented updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting, showing a favorable safety profile with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results